Jardiance(Empagliflozin)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$11.43B
Medicare cost, 2024
$11.43B
Medicare cost, 2024
Medicare drug plans spent $11.4 billion on Jardiance (empagliflozin) in 2024, for 11.4 million prescriptions and refills filled by 2.5 million patients. It ranks 3rd among all drugs by Medicare drug plan spending. Spending rose 29% from 2023 to 2024. California accounts for the most spending ($1.2 billion, 11% of the total).
Medicare cost, 2024
$11.43B
+29.4% from 2023
Prescriptions
11.4M
$1,005.97 per claim
Patients
2.5M
380,533 prescribers
Total spending, 2024
$11.44B
$4,496.46 per patient
Questions and answers
How much does Medicare spend on Jardiance?
Medicare prescription drug plans paid $11.43B for Jardiance in 2024, for 11,364,702 prescriptions and refills to 2,542,517 patients (up 29.4% from 2023). The average cost per claim was $1,005.97.
Which state spends the most on Jardiance?
California had the highest Medicare cost for Jardiance in 2024: $1.21B for 1,288,267 claims, followed by New York ($875.8M).
Who prescribes Jardiance the most?
Stella Ilyayeva, internal medicine in Rego Park, NY, had the highest Medicare cost for Jardiance in 2024: 5,520 claims costing $4.2M.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Jardiance was $11.44B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Jardiance, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Stella Ilyayeva Rego Park, NY | Internal Medicine | 5,520 | 1,051 | $4.2M |
| Eugenio Angueira-Serrano Miami, FL | Endocrinology | 3,055 | 671 | $2.6M |
| Bashar G Saad San Dimas, CA | Endocrinology | 1,696 | 433 | $1.5M |
| John T Funai Lihue, HI | Cardiology | 1,030 | 325 | $1.5M |
| Cheng-Yang C Tuan San Francisco, CA | Endocrinology | 1,216 | 288 | $1.5M |
| Lane M Frey Thibodaux, LA | Endocrinology | 1,280 | 288 | $1.4M |
| Eliscer Guzman New York, NY | Internal Medicine | 1,326 | 358 | $1.4M |
| Sharon H Kim Bronx, NY | Endocrinology | 1,345 | 326 | $1.4M |
| Wei Y Sun New York, NY | Nephrology | 2,074 | 318 | $1.3M |
| Enrique J Griego McAllen, TX | Family Practice | 1,130 | 335 | $1.3M |
| Mauricio Melhado West Palm Beach, FL | Cardiology | 1,732 | 356 | $1.3M |
| 1710074026 | Internal Medicine | 1,242 | 257 | $1.3M |
| Seshadri Das Staten Island, NY | Endocrinology | 940 | 294 | $1.3M |
| 1982659660 | Endocrinology | 1,686 | 267 | $1.3M |
| Cres P Miranda Jr. Las Vegas, NV | Cardiology | 934 | 320 | $1.3M |
| Helen L Slone Vineland, NJ | Endocrinology | 962 | 287 | $1.2M |
| Mark T Hoffmann Wausau, WI | Interventional Cardiology | 1,114 | 268 | $1.2M |
| Ronak S Chaudhari Bowling Green, KY | Endocrinology | 1,261 | 278 | $1.2M |
| Monica G Robles Anniston, AL | Endocrinology | 1,041 | 270 | $1.2M |
| Abdul Al-Kassab Rochester Hills, MI | Endocrinology | 856 | 255 | $1.2M |
| Thomas-Duythuc to Reno, NV | Cardiology | 819 | 274 | $1.1M |
| Mohammad T Ijaz Zanesville, OH | Endocrinology | 1,182 | 249 | $1.1M |
| Opada Alzohaili Dearborn, MI | Endocrinology | 1,446 | 297 | $1.1M |
| Joselito C Cabaccan San Jose, CA | Endocrinology | 885 | 277 | $1.1M |
| Ameya Hodarkar Burlington, MA | Endocrinology | 1,069 | 239 | $1.1M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 280,036 | 5,651,571 | 1,320,699 | $5.85B |
| 2023 | 336,857 | 8,149,965 | 1,881,944 | $8.84B |
| 2024 | 380,533 | 11,364,702 | 2,542,517 | $11.43B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Boehringer Ing. | 11,368,280 | $11.44B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 25
- RxNorm concept IDs
- 1545658, 1545664, 1545666, 1545668
- Application numbers
- NDA204629
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 74,862 side-effect reports named empagliflozin, the active ingredient of Jardiance (reports from 2013 on). 45,232 of them (60.4%) were serious, 3,696 named a death and 24,554 named a hospital stay. The reactions named most often were diabetic ketoacidosis, nausea and blood glucose increased. 46,205 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
74,862
10,047 in 2025 (-3.0% from 2024)
Serious
60.4%
45,232 reports
Deaths named
3,696
4.9% of reports
Hospital stays
24,554
32.8% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Jardiance?
74,862 reports from 2013 through September 2026 named empagliflozin, the active ingredient of Jardiance. 45,232 of them (60.4%) were serious, 3,696 named a death and 24,554 named a hospital stay.
What are the most reported side effects of Jardiance?
4,231 reports named diabetic ketoacidosis, the reaction named most often, followed by nausea (4,062) and blood glucose increased (3,640). In the last 5 years the reaction named most often was nausea (2,650 reports). A report can name several reactions.
How many side-effect reports named Jardiance in 2025?
10,047 reports were received in 2025 (-3.0% from 2024). 2026 so far: 7,895 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Jardiance caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Jardiance caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Drug approvals (1 approval on file for empagliflozin) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (empagliflozin) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.